The FDA has approved Mavyret for the treatment of all 6 genotypes of hepatitis C virus in children 12 to 17 years old or weighing at least 45kg.
All articles by Diana Ernst, RPh
A recall of Ketorolac Tromethamine Injection has been issued following microbial growth contamination.
The Food and Drug Administration (FDA) has approved Dengvaxia (dengue tetravalent vaccine, live; Sanofi) for the prevention of dengue disease caused by dengue virus serotypes 1, 2, 3 and 4.
A new clinical guideline on the diagnosis and treatment of recurrent urinary tract infections in women was released by AUA.
The NDA for the long-acting injectable formulation of rilpivirine + cabotegravir (Janssen and ViiV Healthcare) for HIV has been submitted.
A recent report published in the American Journal of Case Reports describes a rare case of drug reaction with eosinophilia and systemic symptoms (DRESS)-induced agranulocytosis in a patient treated with the beta-lactam antibiotic oxacillin.
The FDA has expanded the approval of Avycaz to include pediatric patients aged ≥3 months for the treatment of complicated intra-abdominal infections.
A study shows Descovy for PrEP demonstrated that the treatment was non-inferior to Truvada for HIV prevention.
The approval was based on data from the Td537 study which included individuals 18-64 years old who had received a dose of Adacel 8-12 years prior (N=1330).
The information, posted to the Food and Drug Administration (FDA) website, states that both the Recombivax HB adult (10mcg/mL) and dialysis (40mcg/mL) formulations are not expected to be available in 2019.